SCHEMBL4282123

SCHEMBL4282123

CC1(C)C2=CC=C3CCCC[C@@H]3[C@@]2(C)C=CC1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29039653 0.63 CYP19A1 (0.31)
SCHEMBL486034 0.53 ESR1 (0.36)
SCHEMBL30644226 0.51 TLR4 (0.43)
SCHEMBL19003295 0.51 KDM4E (0.31)
SCHEMBL16053799 0.49 HTT (0.38)
SCHEMBL28628472 0.48 CYP19A1 (0.35)
SCHEMBL4063047 0.48 ESR1 (0.31)
SCHEMBL5365813 0.48 CA1 (0.34)
SCHEMBL37526 0.48
SCHEMBL27985569 0.48

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143279-A1 Methods and compositions for treating metabolic disorders PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2009-06-04 US disclosed
WO-2008156654-A2 CYTOSKELETON MODULATORS FOR TREATING METABOLIC DISORDERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2008-12-24 WO disclosed